{
    "ticker": "NPCT",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage immunotherapy company focused on harnessing the power of the immune system to treat cancer and other diseases. Founded in 2015 by Dr. Patrick Soon-Shiong, NantKwest aims to pioneer the development of natural killer (NK) cell therapy, a type of immunotherapy that utilizes the body's own immune cells to target and destroy malignant cells. The company has developed a proprietary platform, known as the NantKwest Cell Therapy Platform, which is designed to enhance the potency and efficacy of NK cells for therapeutic use. NantKwest is advancing multiple clinical programs, including treatments for solid tumors and hematological malignancies, with an emphasis on personalized medicine. The company is committed to innovative research and collaboration with leading academic institutions and healthcare organizations to bring transformative therapies to patients. With a growing pipeline of product candidates, NantKwest seeks to redefine the standard of care in oncology and improve patient outcomes through groundbreaking approaches to immunotherapy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Culver City, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "Dr. Patrick Soon-Shiong",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://investors.nantkwest.com",
    "key_executives": [
        {
            "name": "Dr. Patrick Soon-Shiong",
            "position": "CEO"
        },
        {
            "name": "Dr. Arlene Morris",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "NK Cell Therapy",
                "NantKwest Clinical Programs"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Explore NantKwest, Inc., a leader in immunotherapy focused on harnessing NK cell therapy to treat cancer and other diseases. Discover our innovative pipeline and commitment to patient care.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "NK Cell Therapy",
            "Cancer Treatment",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does NantKwest focus on?",
            "answer": "NantKwest focuses on developing immunotherapy solutions, particularly using natural killer (NK) cell therapy to treat cancer."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "Dr. Patrick Soon-Shiong is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Culver City, California, USA."
        },
        {
            "question": "What are NantKwest's main products?",
            "answer": "NantKwest's main products include NK cell therapies and various clinical programs targeting cancer."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "CRBP",
        "MRNA",
        "BMY",
        "JNJ"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "AMGN",
        "GILD"
    ]
}